IFC Holdings Incorporated FL Sells 15,227 Shares of Pfizer (PFE)

IFC Holdings Incorporated FL trimmed its stake in Pfizer (NYSE:PFE) by 22.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 53,159 shares of the biopharmaceutical company’s stock after selling 15,227 shares during the period. IFC Holdings Incorporated FL’s holdings in Pfizer were worth $1,925,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Mutual of America Capital Management LLC increased its position in Pfizer by 3.3% during the 4th quarter. Mutual of America Capital Management LLC now owns 749,350 shares of the biopharmaceutical company’s stock valued at $27,141,000 after buying an additional 24,181 shares in the last quarter. Fiduciary Financial Services of The Southwest Inc. TX increased its position in Pfizer by 1.4% during the 4th quarter. Fiduciary Financial Services of The Southwest Inc. TX now owns 175,082 shares of the biopharmaceutical company’s stock valued at $6,341,000 after buying an additional 2,485 shares in the last quarter. Resources Investment Advisors Inc. increased its position in Pfizer by 80.5% during the 4th quarter. Resources Investment Advisors Inc. now owns 20,532 shares of the biopharmaceutical company’s stock valued at $743,000 after buying an additional 9,154 shares in the last quarter. Investment Partners Ltd. OH ADV increased its position in Pfizer by 5.9% during the 4th quarter. Investment Partners Ltd. OH ADV now owns 33,784 shares of the biopharmaceutical company’s stock valued at $1,224,000 after buying an additional 1,873 shares in the last quarter. Finally, Chicago Equity Partners LLC increased its position in Pfizer by 2.7% during the 4th quarter. Chicago Equity Partners LLC now owns 259,690 shares of the biopharmaceutical company’s stock valued at $9,406,000 after buying an additional 6,850 shares in the last quarter. 71.20% of the stock is owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

In other news, EVP Rady A. Johnson sold 27,323 shares of the company’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $36.55, for a total value of $998,655.65. Following the sale, the executive vice president now owns 70,332 shares in the company, valued at $2,570,634.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $37.19, for a total value of $353,676.90. Following the completion of the sale, the insider now owns 36,959 shares in the company, valued at approximately $1,374,505.21. The disclosure for this sale can be found here. Insiders sold 248,037 shares of company stock worth $9,064,785 in the last 90 days. Company insiders own 0.06% of the company’s stock.

Shares of PFE stock opened at $35.17 on Monday. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $209,362.27, a PE ratio of 13.27, a PEG ratio of 1.76 and a beta of 0.90. Pfizer has a fifty-two week low of $31.67 and a fifty-two week high of $39.43.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The firm had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. During the same quarter in the prior year, the business earned $0.47 earnings per share. The company’s revenue was up .6% compared to the same quarter last year. research analysts anticipate that Pfizer will post 2.96 EPS for the current year.

Pfizer announced that its Board of Directors has approved a share repurchase program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s leadership believes its shares are undervalued.

Several research analysts recently issued reports on the company. BMO Capital Markets set a $39.00 target price on Pfizer and gave the company a “buy” rating in a research report on Tuesday, January 30th. SunTrust Banks reaffirmed a “hold” rating and set a $40.00 target price (up from $33.00) on shares of Pfizer in a research report on Monday, January 29th. Morgan Stanley upped their target price on Pfizer from $41.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. UBS set a $42.00 target price on Pfizer and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, Societe Generale set a $40.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Wednesday, January 31st. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $39.25.

TRADEMARK VIOLATION WARNING: “IFC Holdings Incorporated FL Sells 15,227 Shares of Pfizer (PFE)” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3342744/ifc-holdings-incorporated-fl-sells-15227-shares-of-pfizer-pfe.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Stitch Fix  & LightInTheBox  Critical Survey
Stitch Fix & LightInTheBox Critical Survey
Head-To-Head Contrast: DavidsTea  vs. Sainsbury’s
Head-To-Head Contrast: DavidsTea vs. Sainsbury’s
Sinclair Broadcast Group  Expected to Announce Earnings of $0.73 Per Share
Sinclair Broadcast Group Expected to Announce Earnings of $0.73 Per Share
Comparing Revolution Lighting Technologies  and Energy Focus
Comparing Revolution Lighting Technologies and Energy Focus
HCP, Inc.  Receives $27.50 Consensus Price Target from Brokerages
HCP, Inc. Receives $27.50 Consensus Price Target from Brokerages
Brokerages Set Eni  Target Price at $30.75
Brokerages Set Eni Target Price at $30.75


Leave a Reply

© 2006-2018 Ticker Report. Google+.